Biomarker: T003-IgE Common Silver Birch

Overview

T003-IgE measures immunoglobulin E antibodies directed against common silver birch pollen, generally identified as Betula verrucosa or Betula pendula. IgE is an immune protein involved in immediate allergic reactions, including allergic rhinitis and asthma. A detectable or elevated result indicates sensitization to birch pollen but does not by itself establish symptomatic allergy or predict reaction severity. Birch-specific IgE is clinically useful when interpreted with exposure history and symptoms, and it may help assess cross-reactivity with related tree pollens and certain foods through the major birch allergen Bet v 1.

Clinical Use Cases

Evaluation of suspected birch pollen allergy and seasonal allergic rhinitis.
Support for diagnosing pollen-associated asthma when symptoms correlate with birch exposure.
Identification of sensitization when skin testing is unsuitable, unavailable, or affected by medications or skin disease.
Selection of relevant allergens for avoidance counseling or allergen immunotherapy.
Assessment of possible cross-reactive pollen-food allergy involving foods such as apples, stone fruits, hazelnuts, and some vegetables, particularly when component testing for Bet v 1 is available.
Monitoring sensitization in clinical research, including studies of birch-pollen immunotherapy.

Specimen Types

Venous whole blood, with serum used for analysis.
Serum or plasma, depending on the laboratory assay and validated specimen requirements.

Measurement Methods

Quantitative serum allergen-specific IgE immunoassay.
Fluorescence enzyme immunoassay or other solid-phase immunoassays.
Enzyme-linked immunosorbent assay in research or selected laboratory settings.
Component-resolved immunoassay for antibodies to individual birch allergens, especially Bet v 1.
Skin-prick testing with birch pollen extract as a related, non-blood method for assessing IgE-mediated sensitization.

Test Preparation and Influencing Factors

Fasting is generally not required for a specific IgE blood test.
Patients should report all medications, particularly antihistamines and other allergy treatments. Medication changes should only be made when directed by a healthcare professional.
Results should be interpreted with symptom history, timing of symptoms, geographic exposure, and local birch pollen seasons.
A positive result indicates sensitization and does not confirm that exposure causes clinical symptoms.
The measured IgE concentration does not reliably predict the severity of an allergic reaction.
Cross-reactive antibodies to related pollen or plant allergens may contribute to positive results; component testing can help distinguish genuine birch sensitization from some patterns of broader cross-reactivity.
Total IgE, smoking, parasitic infection, age, and other atopic conditions can influence overall IgE measurements, but they do not replace interpretation of birch-specific IgE.